Centene Corporation's Stock Analysis

Centene Appoints New Corporate Controller and Chief Accounting Officer

Centene Corporation has appointed Theodore Pienkos as the new Corporate Controller and Chief Accounting Officer, effective March 18, 2026. Pienkos, a CPA with extensive experience at Centene since 2011, will receive a base salary of $440,000 and a target bonus of 60% of his salary, along with participation in the company's incentive compensation programs. His prior roles include Deputy Corporate Controller and Vice President of Finance & Accounting.

Kate Casso, who has been with Centene for over 20 years and served as the previous Corporate Controller, will transition to the role of Senior Vice President, Finance Operations and Innovation. In her new position, she will focus on innovation across the enterprise while continuing to oversee various finance teams, including Data Analytics and Financial Planning and Analysis.

Mar 24, 2026 17:15:16

Centene Plans Presentation and Announces Debt Redemption Details

Centene Corporation is scheduled to present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 8:30 a.m. EDT, where it will reaffirm its 2026 full-year GAAP diluted earnings per share guidance of over $1.98 and adjusted diluted EPS guidance of over $3.00. A live audio webcast of the presentation will be available on the company's website, along with a replay afterwards for investors to access.

Additionally, Centene has announced a partial redemption of $1 billion of its outstanding 4.25% Notes due December 15, 2027, which will take place on March 25, 2026. Following this redemption, approximately $1.19 billion of the 2027 Notes will remain outstanding. The redemption price will be 100% of the principal amount plus any accrued interest up to the redemption date.

Mar 09, 2026 18:20:33

Centene Reaffirms 2026 Earnings Guidance for Investors

Centene Corporation's senior management will meet with investors during the week of February 23, 2026, to reaffirm its guidance for the year. The company expects its GAAP diluted earnings per share (EPS) to exceed $1.98 and its adjusted diluted EPS to exceed $3.00 for 2026. This guidance aligns with previously provided information on February 6, 2026, and is intended to give investors clarity on the company's financial expectations.

The company also presents non-GAAP financial measures to help investors better understand its core performance over time. These measures exclude certain expenses, such as amortization of acquired intangible assets and acquisition-related costs, which Centene believes provides a clearer view of its ongoing operations. Investors are encouraged to review Centene's full financial statements and reports for comprehensive insights, as non-GAAP measures may differ from those used by other companies.

Feb 20, 2026 21:32:27

Centene Reports Q4 2025 Results and 2026 Earnings Guidance

Centene Corporation announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting a GAAP diluted loss per share of $(13.53) primarily due to a goodwill impairment of $6.7 billion. Adjusted diluted earnings per share for the full year were $2.08, with premium and service revenues increasing 20% to $174.6 billion. The health benefits ratio for the full year was 91.9%, reflecting increased medical costs and changes in the Marketplace and Medicaid segments.

Looking ahead, Centene expects adjusted diluted earnings per share to exceed $3.00 for the 2026 fiscal year. The company reported a cash flow from operations of $5.1 billion for 2025 and had a total debt of $17.4 billion at year-end. Additionally, Centene is in the process of divesting its remaining Magellan Health businesses, which has led to recorded impairment charges totaling $513 million. The company continues to manage its SG&A expenses effectively, achieving an adjusted SG&A expense ratio of 7.4% for the year.

Feb 05, 2026 20:52:22

Centene to Present Financial Outlook at UBS Healthcare Conference

Centene Corporation will participate in the UBS 2025 Global Healthcare Conference on November 11, 2025, at 10:15 a.m. EST, where management will discuss the company's financial outlook. The company has reaffirmed its previously issued full-year 2025 GAAP forecast of a diluted loss per share not exceeding $(12.85) and an adjusted diluted earnings per share forecast of at least $2.00. A live audio webcast of the presentation will be available on Centene's website, and a replay will be accessible afterward.

The company is providing non-GAAP financial measures to help investors assess its ongoing operations and performance consistency. These measures exclude certain expenses, allowing for a more meaningful understanding of Centene's core performance over time. Investors are encouraged to review the company's consolidated financial statements and publicly filed reports for a comprehensive view of its financial status, as the non-GAAP measures may differ from those used by other companies.

Nov 10, 2025 16:40:53

Centene Reports Q3 2025 Results with Goodwill Impairment Impact

Centene Corporation announced its financial results for the third quarter of 2025, reporting a GAAP diluted loss per share of $(13.50) primarily due to a non-cash goodwill impairment of $6.7 billion. The adjusted diluted earnings per share (EPS) for the quarter was $0.50, benefiting from a lower effective tax rate. The company’s premium and service revenues increased by 22% year-over-year, reaching $44.9 billion, driven by growth in its Medicare and Medicaid segments despite a decline in Medicaid membership. The health benefits ratio for the quarter was 92.7%, reflecting increased medical costs in the Marketplace and Medicaid sectors.

Centene has updated its full-year adjusted diluted EPS forecast to at least $2.00, an increase of $0.25 from previous estimates. The company reported cash and investments totaling $38.8 billion and maintained a debt-to-capital ratio of 45.5% as of September 30, 2025. Additionally, Centene's SG&A expense ratio improved to 7.0% from 8.3% year-over-year, indicating better expense management amidst revenue growth. The company will host a conference call to discuss these results and provide further insights to investors.

Oct 28, 2025 20:02:04

Centene to Present at Deutsche Bank Healthcare Summit

Centene Corporation will participate in the Deutsche Bank 2025 Healthcare Summit on September 11, 2025, at 8:00 a.m. EDT. Management will discuss the company’s business and financial results through August, aligning with its previously issued forecast of approximately $1.75 adjusted diluted earnings per share (EPS). A live audio webcast of the presentation will be available, along with a replay on the company's website.

The company is providing non-GAAP financial measures to help investors assess its ongoing operations and performance consistently. These measures exclude certain expenses, allowing for a clearer understanding of core performance over time. However, Centene cautions that these non-GAAP measures may differ from those used by other companies, and it encourages investors to review its consolidated financial statements for a complete picture of its financial health.

Sep 10, 2025 21:40:56

Centene Director Thomas R. Greco Resigns Effective August 2025

Director Thomas R. Greco has resigned from Centene Corporation, effective August 22, 2025. His resignation is attributed to increased professional responsibilities following his appointment as CEO of FleetPride, Inc. There were no disputes or disagreements between Mr. Greco and the Company or its Board regarding operations or policies.

Following Mr. Greco's departure, the Board of Directors will be reduced to nine members. This change in the board composition may impact the governance structure of the Company as it continues its operations.

Aug 15, 2025 16:29:37

Centene Director Resignation Reduces Board Size to Ten

Wayne S. DeVeydt has resigned from his position as a director of Centene Corporation, effective immediately as of August 1, 2025. His resignation was not due to any disputes or disagreements with the company or its Board of Directors.

Following Mr. DeVeydt's departure, the Board has adjusted its composition, reducing the number of directors to ten. This change may impact the governance structure of the company.

Aug 04, 2025 16:36:48

Centene Reports Second Quarter 2025 Financial Results

Centene Corporation reported a diluted loss per share of $(0.51) for the second quarter of 2025, with an adjusted diluted loss per share of $(0.16). The company experienced an 18% increase in premium and service revenues, reaching $42.5 billion, primarily due to growth in its Medicare and Marketplace segments. However, the health benefits ratio rose to 93.0% from 87.6% in the previous year, attributed to increased medical costs and a reduction in risk adjustment revenue estimates. Operating cash flow was reported at $1.8 billion, reflecting improved timing of pharmacy rebate remittances.

As of June 30, 2025, Centene maintained cash, investments, and restricted deposits totaling $37.5 billion, with medical claims liabilities amounting to $20.1 billion. The company’s total debt stood at $17.6 billion, with no borrowings on its $4 billion revolving credit facility. Centene's management is focused on addressing the trends impacting performance and aims to adapt to the evolving market landscape to deliver value to its stakeholders.

Jul 24, 2025 21:46:22